Association between EGFR gene polymorphisms, skin rash and response to anti‐EGFR therapy in metastatic colorectal cancer patients. Issue 10 (October 2014)

• Record Type: Journal Article
• Authors: Jaka, Ane; Gutiérrez‐Rivera, Araika; Ormaechea, Nerea; Blanco, Jesus; La Casta, Adelaida; Sarasqueta, Cristina; Izeta, Ander; Tuneu, Anna
• Is Part Of: Experimental dermatology. Volume 23:Issue 10(2014:Oct.)
• Page Start: 751
• Page End: 753
• Publication Date: 2014-10
• Subjects: Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.12510
• Languages: English
• ISSNs: 0906-6705

Abstract

<abstract abstract-type="main" id="exd12510-abs-0001"> <title>Abstract</title> <p>Cetuximab and panitumumab are epidermal growth factor receptor (EGFR) inhibitors used in metastatic colorectal cancer (mCRC). Most patients develop a papulopustular rash that may predict tumor response to treatment. <italic>EGFR</italic> gene polymorphisms may also determine tumor response and appearance of skin rash. We hypothesized an association between <italic>EGFR</italic> gene polymorphisms, papulopustular rash and response to anticancer treatment. Four EGFR polymorphisms (−216, −191, CA‐SSR, R521K) were analysed in 51 patients with mCRC receiving anti‐EGFR. Severity of cutaneous rash and tumor response was measured following standard scales. We report an association between SNP‐216 and tumor response (<italic>P</italic> = 0.003): no tumor progression occurred in TT genotype. Moreover, 92.3% of the responder patients developed skin rash, 62.9% of them presenting a grade ≥2 (<italic>P</italic> = 0.015). Thus, although underpowered, our preliminary data suggest that SNP‐216 polymorphism of the <italic>EGFR</italic> gene could be useful in predicting tumor response and the appearance of severe skin rash might also be associated.</p> </abstract>